Preclinical Models of Multiple Sclerosis: Advantages and Limitations Towards Better Therapies

E-ISSN： 1875-533x|23|14|1442-1459

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.23, Iss.14, 2016-04, pp. : 1442-1459

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging therapies in multiple sclerosis

By Farrell Rachel Heaney Dominic Giovannoni Gavin

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 4, 2005-11 ,pp. : 797-816

Informa Healthcare

Access to resources Recommend Favorite

Antigen-specific therapies in multiple sclerosis

By Giacomini Paul S Bar-Or Amit

Expert Opinion on Emerging Drugs, Vol. 14, Iss. 3, 2009-09 ,pp. : 551-560

Informa Healthcare

Access to resources Recommend Favorite

Induction and Escalation Therapies in Multiple Sclerosis

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 14, Iss. 1, 2015-03 ,pp. : 26-34

Bentham Science Publishers

Access to resources Recommend Favorite

Animal models of multiple sclerosis

PHARMAKON, Vol. 2, Iss. 6, 2014-11 ,pp. : 429-434

Govi-Verlag

Access to resources Recommend Favorite

Recent advances in preclinical drug development in multiple sclerosis

By Hoban C.J.

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 7, 1998-07 ,pp. : 831-854

Informa Healthcare

Access to resources Recommend Favorite